Tags: Allergies | peanut | allergy | patch | dbv

'Breakthrough' Peanut Allergy Treatment Hits Market

Wednesday, 22 Oct 2014 08:20 AM

French biotech firm DBV Technologies - developer of what it says is a breakthrough treatment for peanut allergy sufferers - makes its U.S. market debut on Wednesday, with a Nasdaq listing set to raise funds for further research.

The Paris-listed company, which develops immunotherapy patches for patients with potentially fatal food allergies, is issuing 2.67 million new shares worldwide via a U.S. listing and a private placement which together will raise at least 90 million euros ($114 million).

"This fundraising will enable us to significantly strengthen our structures in France, notably in research and development," Chief Executive Pierre-Henri Benhamou told Reuters in an interview earlier this week.

DBV also develops patches for milk and dust mite allergies, but its "Viaskin Peanut" product is the most advanced and represents up to 75 percent of the company's potential value, according to some analysts.

Benhamou believes the product could be a blockbuster with over $1 billion in global sales.

Around three million people suffer from peanut allergy in the United States alone, where the average consumer eats over six pounds of peanut products a year, mainly in the form of a wildly popular spread - peanut butter.

DBV's desensitization patch administers small amounts of peanut allergens into the outer layers of the skin, where it activates the immune system without bringing the antigen into the bloodstream, as that could cause an allergic shock.

Following encouraging mid-stage clinical results, DBV hopes to start Phase III clinical trials by the first quarter of 2016, for a commercial launch in 2017.

There are currently no such immunotherapy patches on the market and DBV plans to sell the peanut patch on its own, without licensing it to a bigger partner.

The firm says it won't need a big sales force to pitch the product to doctors as there are only several thousand allergy specialists in the United States. "It's really within our reach," said DBV's finance director David Schilansky.

DBV would not comment on the potential price of the patch, which Bryan Garnier & Co's analyst Mathieu Chabert estimates will exceed $3,500 per patient per year.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Health-News
French biotechfirm DBV Technologies - developer of what it says is a breakthrough treatment for peanut allergy sufferers - makes its U.S. market debut on Wednesday, with a Nasdaq listing set to raise funds for further research.The Paris-listed company, which develops...
peanut, allergy, patch, dbv
349
2014-20-22
Wednesday, 22 Oct 2014 08:20 AM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved